February 2025 Penny Stocks To Watch For Growth

As the U.S. stock market seeks to recover from a recent slump, with major indices experiencing a slight rebound, investors are closely watching for signs of stability and growth. In this context, penny stocks—often seen as smaller or newer companies—continue to offer intriguing opportunities for those willing to explore beyond the mainstream options. Despite being considered somewhat outdated, these stocks remain relevant due to their potential for significant returns when backed by strong financials and promising prospects.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$123.69M	★★★★★★
BAB (OTCPK:BABB)	$0.8998	$6.27M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.90	$395.93M	★★★★☆☆
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
North European Oil Royalty Trust (NYSE:NRT)	$4.55	$41.08M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.58	$78.86M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.44	$46.86M	★★★★★★
PHX Minerals (NYSE:PHX)	$4.11	$149.92M	★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)	$1.32	$24.12M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8239	$76.37M	★★★★★☆

Click here to see the full list of 735 stocks from our US Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

China Natural Resources (NasdaqCM:CHNR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: China Natural Resources, Inc., with a market cap of $5.98 million, operates through its subsidiaries in the exploration and mining of metal properties in the People’s Republic of China.

Operations: No specific revenue segments are reported for China Natural Resources, Inc.

Market Cap: $5.98M

China Natural Resources, Inc., with a market cap of US$5.98 million, operates in the mining sector and remains pre-revenue, generating less than US$1 million. The company faces challenges with short-term liabilities exceeding its assets significantly (CN¥177.8M vs CN¥5.9M). Despite having no debt and a seasoned management team with an average tenure of 8.5 years, it is unprofitable with declining earnings over the past five years at 9% annually. Recently granted an extension to meet Nasdaq's minimum bid price requirement by June 30, 2025, its share price remains volatile but undiluted over the past year.

• Jump into the full analysis health report here for a deeper understanding of China Natural Resources.
• Understand China Natural Resources' track record by examining our performance history report.

Identiv (NasdaqCM:INVE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Identiv, Inc. is a security technology company offering secure identification and physical security solutions globally, with a market cap of $83.84 million.

Operations: The company's revenue is primarily derived from the Americas at $75.12 million, followed by Europe and The Middle East at $17.78 million, and the Asia-Pacific region contributing $11.32 million.

Market Cap: $83.84M

Identiv, Inc., with a market cap of US$83.84 million, is navigating the penny stock landscape with some strategic moves but faces challenges. The company remains unprofitable and is not expected to achieve profitability in the near term. However, it benefits from being debt-free and has short-term assets significantly exceeding liabilities (US$166 million vs US$19 million), providing a solid cash runway for over three years even if free cash flow declines. Recent executive changes include hiring Kim Macaulay as SVP of Sales, Marketing, and Business Development to drive growth initiatives in high-value segments like Bluetooth Low Energy technology adoption.

• Get an in-depth perspective on Identiv's performance by reading our balance sheet health report here.
• Gain insights into Identiv's future direction by reviewing our growth report.

Integrated BioPharma (OTCPK:INBP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Integrated BioPharma, Inc., along with its subsidiaries, focuses on manufacturing, distributing, marketing and selling vitamins, nutritional supplements and herbal products mainly in the United States and Luxembourg, with a market cap of $9.33 million.

Operations: The company generates revenue primarily from Contract Manufacturing, which accounts for $49.72 million, and Other Nutraceutical Businesses, contributing $2.40 million.

Market Cap: $9.33M

Integrated BioPharma, Inc., with a market cap of US$9.33 million, has recently transitioned to profitability, reporting net income of US$0.116 million for the second quarter ending December 31, 2024. This marks an improvement from a net loss in the previous year. The company is debt-free and its short-term assets (US$18.2 million) exceed both short-term and long-term liabilities, indicating strong financial stability within its niche market. Despite past earnings declines averaging 36.9% annually over five years, recent results show sales growth to US$12.61 million for the quarter compared to US$11.51 million last year, suggesting potential recovery momentum.

• Click here to discover the nuances of Integrated BioPharma with our detailed analytical financial health report.
• Learn about Integrated BioPharma's historical performance here.

Summing It All Up

• Get an in-depth perspective on all 735 US Penny Stocks by using our screener here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com